Mar Vista Investment Partners, LLC, an investment management company, released the “Mar Vista U.S. Quality Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The stock market rose in 2024 and carried on through the fourth quarter, as investors welcomed the growing optimism following the presidential election. For the year, the S&P 500® Index (“S&P 500®”) increased by 25.0%, its second straight consecutive annual gain above 20%. In the fourth quarter, the strategy returned -0.18% net-of-fees compared to +2.74% and +2.41% returns for the Russell 1000® Index and the S&P 500® Index, respectively. In addition, please check the fund’s top five holdings to know its best picks in 2024.
In its fourth quarter 2024 investor letter, Mar Vista U.S. Quality Strategy emphasized stocks such as Mettler-Toledo International Inc. (NYSE:MTD). Mettler-Toledo International Inc. (NYSE:MTD) is a precision instruments and services manufacturer and supplier. The one-month return of Mettler-Toledo International Inc. (NYSE:MTD) was -4.50%, and its shares gained 7.64% of their value over the last 52 weeks. On February 21, 2025, Mettler-Toledo International Inc. (NYSE:MTD) stock closed at $1,286.54 per share with a market capitalization of $26.91 billion.
Mar Vista U.S. Quality Strategy stated the following regarding Mettler-Toledo International Inc. (NYSE:MTD) in its Q4 2024 investor letter:
“Healthcare stocks in general, and Life Science tool businesses more specifically, ended 2024 on a downbeat as investor sentiment is still cautious on the market’s post-Covid recovery. Hopes for an above-average industry growth rebound in 2025 were muted by managements’ more cautious guidance. Investor concerns over the Trump administration’s healthcare leadership and policies further dampened optimism for a strong 2025. Tariff impacts, NIH funding and Biotech/pharma spending top the list of investor concerns. We believe Mettler-Toledo International Inc.’s (NYSE:MTD) and Danaher’s secular growth opportunities stay intact. Both businesses compete in key, defensible segments of the industry’s value chain and have strong pricing power and margin expansion opportunities. Long-term secular drivers for scientific research and commercialization of biologic therapeutics and molecular diagnostic should drive above-average growth for both businesses.”
A close-up of a laboratory instrument, with a technician making precise adjustments.
Mettler-Toledo International Inc. (NYSE:MTD) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 50 hedge fund portfolios held Mettler-Toledo International Inc. (NYSE:MTD) at the end of the fourth quarter which was 42 in the previous quarter. Mettler-Toledo International Inc.’s (NYSE:MTD) sales were $1.045 billion in the fourth quarter, representing an increase of 12% in local currency and in US dollars compared to Q4 2023. While we acknowledge the potential of Mettler-Toledo International Inc. (NYSE:MTD) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article we discussed Mettler-Toledo International Inc. (NYSE:MTD) and shared the list of best scientific instruments stocks to buy. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.